L
Luis Hernandez
Researcher at University of Los Andes
Publications - 17
Citations - 478
Luis Hernandez is an academic researcher from University of Los Andes. The author has contributed to research in topics: Cost effectiveness & Stroke. The author has an hindex of 11, co-authored 17 publications receiving 423 citations.
Papers
More filters
Journal ArticleDOI
An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom
TL;DR: Cost‐effectiveness of early assessment of individuals presenting with subjective memory complaints and treating those with AD with donepezil was evaluated in the United Kingdom.
Journal ArticleDOI
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
Paul Dorian,Thitima Kongnakorn,Hemant Phatak,Dale Rublee,Andreas Kuznik,Tereza Lanitis,Larry Z. Liu,Uchenna H. Iloeje,Luis Hernandez,Gregory Y.H. Lip +9 more
TL;DR: Based on randomized trial data, apixaban is a cost-effective alternative to warfarin and aspirin, in VKA suitable and VKA unsuitable patients with AF, respectively.
Journal ArticleDOI
Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
Gregory Y.H. Lip,Thitima Kongnakorn,Hemant Phatak,Andreas Kuznik,Tereza Lanitis,Larry Z. Liu,Uchenna H. Iloeje,Luis Hernandez,Paul Dorian +8 more
TL;DR: It is projected that apixaban may be a cost-effective alternative to dabigatran 150 mg BID, dabig atran 110 mg BIDs, and rivaroxaban 20 mg once daily for stroke prevention in AF patients from the perspective of the United Kingdom National Health Services.
Journal ArticleDOI
Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps.
Shien Guo,Denis Getsios,Luis Hernandez,Kelly Cho,Kelly Cho,Elizabeth V. Lawler,Elizabeth V. Lawler,Elizabeth V. Lawler,Arman Altincatal,Stephan Lanes,Michael Blankenburg +10 more
TL;DR: The analyses indicate that florbetaben PET has the potential to improve patient outcomes and reduce costs under certain scenarios and key data are unavailable and would be required to confirm its value.
Journal ArticleDOI
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States
TL;DR: It is suggested that long-term treatment with peginterferonbeta-1a improves clinical outcomes at reduced costs compared with interferon beta-1A and glatiramer acetate and should be a valuable addition to managed care formularies for treating patients with RRMS.